NCT03069131COMPLETEDanonymous

A Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial Comparing Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites : Using or Not Using Rifaximin

Sponsor

Source record

Centre Hospitalier Universitaire de Besancon

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Rifaximin, Placebo

Indication / condition

AI-normalized

Cirrhosis

Intervention

Source record

Rifaximin, Placebo

Related intelligence directories

Indication directory: Cirrhosis Modality directory: small molecule Target directory: Rifaximin

Source & freshness

Source record

NCT ID

NCT03069131

Original source

ClinicalTrials.gov

Source last updated

Apr 10, 2025

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03069131

Title

A Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial Comparing Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites : Using or Not Using Rifaximin

Sponsor

Centre Hospitalier Universitaire de Besancon

Status

COMPLETED

Phase

PHASE3

Condition raw

Cirrhosis, Ascites, Peritonitis

Condition normalized

Cirrhosis, Ascites, Peritonitis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Rifaximin, Placebo

Target normalized

Rifaximin, Placebo

Interventions

Rifaximin, Placebo

Public preview

Source record

We wish to perform a multicenter, double-blind RCT with two parallel-group stratified on the center, comparing rifaximin to no rifaximin (placebo) for the primary prophylaxis of SBP in 'severe' cirrhotic patients with large ascites. The primary outcome will be the 12-month survival.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial Comparing Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites : Using or Not Using Rifaximin

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03069131

Status

COMPLETED

Phase

PHASE3

Sponsor

Centre Hospitalier Universitaire de Besancon

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 10, 2025

Internal syncJun 19, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03069131

Indication

Cirrhosis

Modality

small molecule

Target

Rifaximin, Placebo

Intervention

Rifaximin, Placebo

Source record